- Home
- MCR vs CRVS Comparison
MCR vs CRVS Comparison
Compare MCR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- CRVS
- Stock Information
- Founded
- MCR 1989
- CRVS 2014
- Country
- MCR United States
- CRVS United States
- Employees
- MCR N/A
- CRVS N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- CRVS Health Care
- Exchange
- MCR Nasdaq
- CRVS Nasdaq
- Market Cap
- MCR 250.1M
- CRVS 206.5M
- IPO Year
- MCR N/A
- CRVS 2016
- Fundamental
- Price
- MCR $6.34
- CRVS $3.91
- Analyst Decision
- MCR
- CRVS Strong Buy
- Analyst Count
- MCR 0
- CRVS 4
- Target Price
- MCR N/A
- CRVS $15.00
- AVG Volume (30 Days)
- MCR 66.7K
- CRVS 1.4M
- Earning Date
- MCR 01-01-0001
- CRVS 05-08-2025
- Dividend Yield
- MCR 8.52%
- CRVS N/A
- EPS Growth
- MCR N/A
- CRVS N/A
- EPS
- MCR 0.38
- CRVS N/A
- Revenue
- MCR N/A
- CRVS N/A
- Revenue This Year
- MCR N/A
- CRVS N/A
- Revenue Next Year
- MCR N/A
- CRVS N/A
- P/E Ratio
- MCR $16.61
- CRVS N/A
- Revenue Growth
- MCR N/A
- CRVS N/A
- 52 Week Low
- MCR $5.63
- CRVS $1.75
- 52 Week High
- MCR $6.70
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- MCR 64.11
- CRVS 55.05
- Support Level
- MCR $6.21
- CRVS $3.70
- Resistance Level
- MCR $6.35
- CRVS $4.36
- Average True Range (ATR)
- MCR 0.06
- CRVS 0.24
- MACD
- MCR 0.00
- CRVS 0.02
- Stochastic Oscillator
- MCR 93.75
- CRVS 54.08
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).